MAYNE PHARMA GROUP LIMITED (MYX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

MYX - MAYNE PHARMA GROUP LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -4.14
Index: ASX300 | ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -4.14
Mayne Pharma is an Australian pharmaceuticals development and manufacturing company with facilities in Australia and the US. It also provides development and manufacturing services to global clients. It listed in 2007.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$5.25
09 Jul |
OPEN $5.20 |
HIGH $5.30 |
175,166 LOW $5.10 |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -218.8 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 388.4 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 559.0 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -9.6 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -43.41 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -30.98 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -29.16 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -14.10 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -30.98 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -13.25 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -17.5 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 4 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 35 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 39 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 152 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.84 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 20.9 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 5.37 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 229 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 237 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 20 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
MYX STOCK CHART

FNArena News on MYX
1 |
Next Week At A Glance – 23-27 Jun 2025Jun 20 2025 - Weekly Reports |
2 |
Next Week At A Glance – 26-30 May 2025May 23 2025 - Weekly Reports |
3 |
Australian Broker Call *Extra* Edition – May 15, 2025May 15 2025 - Daily Market Reports |
4 |
Australian Broker Call *Extra* Edition – Apr 27, 2025Apr 28 2025 - Daily Market Reports |
5 |
Australian Broker Call *Extra* Edition – Apr 15, 2025Apr 16 2025 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
The Enigma Surrounding ClinuvelJul 03 2025 - Small Caps |
2 |
Rudi’s View: CSL & NextDCMay 08 2025 - Rudi's View |
3 |
Behring Margin Outlook Still Main Game For CSLFeb 13 2025 - Australia |
4 |
Dr Boreham’s Crucible: Arovella TherapeuticsAug 29 2024 - Small Caps |
5 |
ResMed’s Margin Upside ExcitesAug 07 2024 - Australia |
6 |
Dr Boreham’s Crucible: Aroa BiosurgeryJul 29 2024 - Small Caps |
7 |
CSL Shares Breaking FreeJul 23 2024 - Technicals |
8 |
Dr Boreham’s Crucible: SDIJul 19 2024 - Small Caps |
9 |
‘Defensive’ Pharmaceutical Wholesalers In FocusJul 18 2024 - Australia |
10 |
Twists And Turns Of Telix And Australian BiotechJul 10 2024 - Small Caps |